[5-fluorouracil and dihydropyrimidine dehydrogenase].
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the (fluoro) pyrimidine catabolic pathway, and has an important role in 5-fluorouracil (5-FU) pharmacology. Some studies have demonstrated that the fluoropyrimidine catabolite may be related to the toxicity of 5-FU, and tumoral DPD prescribes the response to 5-FU-based therapy. By controlling DPD activity, a new class of fluorinated pyrimidines have been developed to minimize the variability of 5-FU pharmacodynamics, to decrease 5-FU toxicity, and improve its efficacy. Recently, these drugs, referred to as DIFs (DPD inhibitory fluoropyrimidines), have brought us to a new era of oral 5-FU therapy. The importance of DIF in 5-FU-based therapy is reviewed herein.